RiboX Therapeutics Announces First Patient Dosed in Phase I/IIa Clinical Trial of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation ...Middle East

PRINCETON, N.J., March 9, 2025 /PRNewswire/ -- RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, today announced that the first patient was dosed last week in its first-in-human (FIH)...

Read More Details
Finally We wish PressBee provided you with enough information of ( RiboX Therapeutics Announces First Patient Dosed in Phase I/IIa Clinical Trial of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation )

Also on site :

• 6 Subtle Signs of ‘Future Faking’ To Look Out for in Relationships, Psychologists Warn
• U.S. diplomatic negotiators working for ceasefire in Gaza as Israel ramps up attacks
• Pedro Pascal’s Arms Get Their Own Fan Club